Contributions
Abstract: EP1608
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - 25 Biomarkers
Background: Interleukin (IL)-6 is a cytokine with a wide range of biological functions. Its upregulation in the cerebrospinal fluid (CSF) is considered as a marker of central nervous system (CNS) inflammation.
Objective: Our aim was to analyse the diagnostic significance of CSF IL-6 levels among various CNS pseudotumoral inflammatory lesions (PIL) and primary CNS lymphoma (PCNSL).
Methods: We retrospectively analysed the CSF IL-6 concentration in 43 patients admitted for suspected primary CNS lymphoma between February 2014 and march 2017. 28 patients were positively diagnosed with PCNSL, 15 with various inflammatory CNS disorders. We correlated the results with CSF IL-10, a recently established diagnostic biomarker of PCNSL.
IL concentrations were measured by FCM using the cytometric bead array (CBA) technique (BD Biosciences) with a detection limit set at 2.5 pg/ml.
Results: In the PCNSL group, the median CSF IL-6 concentration with interquartile range (IQR) was 8 pg/ml IQR (5 - 18.5). For the patients with other PIL the median concentration was of 70 pg/ml, IQR (5 - 1368). A group comparison showed significantly higher CSF IL-6 levels in patients with PIL compared to PCNSL (p=0.032). Moreover, IL-6 was correlated with CSF cell count for the whole cohort (r=0.45, p=0.002), as well as for the PIL group (r=0.56, p=0.028), but not in PCNSL group (r=0.3, p=0.13). There was no correlation between CSF IL-6 in the two groups (r=0.023, p=0.9). Moreover, we found significantly higher CSF IL-10 levels in patients with PCNSL compared to the group with PIL (p< 0.001).
Conclusion: Our study suggests that CSF IL-6 levels could represent, in addition to CSF IL-10, a useful biomarker in the diagnosis of CNS PIL that may mimic PCNSL.
Disclosure: Nothing to disclose
Abstract: EP1608
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - 25 Biomarkers
Background: Interleukin (IL)-6 is a cytokine with a wide range of biological functions. Its upregulation in the cerebrospinal fluid (CSF) is considered as a marker of central nervous system (CNS) inflammation.
Objective: Our aim was to analyse the diagnostic significance of CSF IL-6 levels among various CNS pseudotumoral inflammatory lesions (PIL) and primary CNS lymphoma (PCNSL).
Methods: We retrospectively analysed the CSF IL-6 concentration in 43 patients admitted for suspected primary CNS lymphoma between February 2014 and march 2017. 28 patients were positively diagnosed with PCNSL, 15 with various inflammatory CNS disorders. We correlated the results with CSF IL-10, a recently established diagnostic biomarker of PCNSL.
IL concentrations were measured by FCM using the cytometric bead array (CBA) technique (BD Biosciences) with a detection limit set at 2.5 pg/ml.
Results: In the PCNSL group, the median CSF IL-6 concentration with interquartile range (IQR) was 8 pg/ml IQR (5 - 18.5). For the patients with other PIL the median concentration was of 70 pg/ml, IQR (5 - 1368). A group comparison showed significantly higher CSF IL-6 levels in patients with PIL compared to PCNSL (p=0.032). Moreover, IL-6 was correlated with CSF cell count for the whole cohort (r=0.45, p=0.002), as well as for the PIL group (r=0.56, p=0.028), but not in PCNSL group (r=0.3, p=0.13). There was no correlation between CSF IL-6 in the two groups (r=0.023, p=0.9). Moreover, we found significantly higher CSF IL-10 levels in patients with PCNSL compared to the group with PIL (p< 0.001).
Conclusion: Our study suggests that CSF IL-6 levels could represent, in addition to CSF IL-10, a useful biomarker in the diagnosis of CNS PIL that may mimic PCNSL.
Disclosure: Nothing to disclose